Circulating Biomarkers to Identify Responders in Cardiac Cell therapy

Jesse V. Jokerst, Nicholas Cauwenberghs, Tatiana Kuznetsova, Francois Haddad, Timothy Sweeney, Jiayi Hou, Yael Rosenberg-Hasson, Eric Zhao, Robert Schutt, Roberto Bolli, Jay H. Traverse, Carl J. Pepine, Timothy D. Henry, Ivonne H Schulman, Lem Moyé, Doris A. Taylor, Phillip C. Yang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as well as 61 STEMI patients treated with placebo. Response to cell therapy was defined by changes in left ventricular ejection fraction, systolic/diastolic volumes, and wall motion indexes. We investigated the clinical value of circulating proteins in outcome prediction using significance testing, partial least squares discriminant analysis, and receiver operating characteristic (ROC) analysis. Responders had higher biomarker levels (76-94% elevated) than non-responders. Several biomarkers had values that differed significantly (P < 0.05) between responders and non-responders including stem cell factor, platelet-derived growth factor, and interleukin-15. We then used these lead candidates for ROC analysis and found multiple biomarkers with values areas under the curve >0.70 including interleukin 15. These biomarkers were not involved in the placebo-treated subjects suggesting that they may have predictive power. We conclude that plasma profiling after STEMI may help identify patients with a greater likelihood of response to cell-based treatment. Prospective trials are needed to assess the predictive value of the circulating biomarkers.

Original languageEnglish (US)
Article number4419
JournalScientific Reports
Volume7
Issue number1
DOIs
StatePublished - Dec 1 2017

Fingerprint

Cell- and Tissue-Based Therapy
Biomarkers
Placebos
Interleukin-15
Discriminant Analysis
Least-Squares Analysis
ROC Curve
Bone Marrow Cells
Stroke Volume
Cytokines
ST Elevation Myocardial Infarction
Proteins
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Jokerst, J. V., Cauwenberghs, N., Kuznetsova, T., Haddad, F., Sweeney, T., Hou, J., ... Yang, P. C. (2017). Circulating Biomarkers to Identify Responders in Cardiac Cell therapy. Scientific Reports, 7(1), [4419]. https://doi.org/10.1038/s41598-017-04801-7

Circulating Biomarkers to Identify Responders in Cardiac Cell therapy. / Jokerst, Jesse V.; Cauwenberghs, Nicholas; Kuznetsova, Tatiana; Haddad, Francois; Sweeney, Timothy; Hou, Jiayi; Rosenberg-Hasson, Yael; Zhao, Eric; Schutt, Robert; Bolli, Roberto; Traverse, Jay H.; Pepine, Carl J.; Henry, Timothy D.; Schulman, Ivonne H; Moyé, Lem; Taylor, Doris A.; Yang, Phillip C.

In: Scientific Reports, Vol. 7, No. 1, 4419, 01.12.2017.

Research output: Contribution to journalArticle

Jokerst, JV, Cauwenberghs, N, Kuznetsova, T, Haddad, F, Sweeney, T, Hou, J, Rosenberg-Hasson, Y, Zhao, E, Schutt, R, Bolli, R, Traverse, JH, Pepine, CJ, Henry, TD, Schulman, IH, Moyé, L, Taylor, DA & Yang, PC 2017, 'Circulating Biomarkers to Identify Responders in Cardiac Cell therapy', Scientific Reports, vol. 7, no. 1, 4419. https://doi.org/10.1038/s41598-017-04801-7
Jokerst JV, Cauwenberghs N, Kuznetsova T, Haddad F, Sweeney T, Hou J et al. Circulating Biomarkers to Identify Responders in Cardiac Cell therapy. Scientific Reports. 2017 Dec 1;7(1). 4419. https://doi.org/10.1038/s41598-017-04801-7
Jokerst, Jesse V. ; Cauwenberghs, Nicholas ; Kuznetsova, Tatiana ; Haddad, Francois ; Sweeney, Timothy ; Hou, Jiayi ; Rosenberg-Hasson, Yael ; Zhao, Eric ; Schutt, Robert ; Bolli, Roberto ; Traverse, Jay H. ; Pepine, Carl J. ; Henry, Timothy D. ; Schulman, Ivonne H ; Moyé, Lem ; Taylor, Doris A. ; Yang, Phillip C. / Circulating Biomarkers to Identify Responders in Cardiac Cell therapy. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{eb1f96069f6243c5bb2e343dbfb5cade,
title = "Circulating Biomarkers to Identify Responders in Cardiac Cell therapy",
abstract = "Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as well as 61 STEMI patients treated with placebo. Response to cell therapy was defined by changes in left ventricular ejection fraction, systolic/diastolic volumes, and wall motion indexes. We investigated the clinical value of circulating proteins in outcome prediction using significance testing, partial least squares discriminant analysis, and receiver operating characteristic (ROC) analysis. Responders had higher biomarker levels (76-94{\%} elevated) than non-responders. Several biomarkers had values that differed significantly (P < 0.05) between responders and non-responders including stem cell factor, platelet-derived growth factor, and interleukin-15. We then used these lead candidates for ROC analysis and found multiple biomarkers with values areas under the curve >0.70 including interleukin 15. These biomarkers were not involved in the placebo-treated subjects suggesting that they may have predictive power. We conclude that plasma profiling after STEMI may help identify patients with a greater likelihood of response to cell-based treatment. Prospective trials are needed to assess the predictive value of the circulating biomarkers.",
author = "Jokerst, {Jesse V.} and Nicholas Cauwenberghs and Tatiana Kuznetsova and Francois Haddad and Timothy Sweeney and Jiayi Hou and Yael Rosenberg-Hasson and Eric Zhao and Robert Schutt and Roberto Bolli and Traverse, {Jay H.} and Pepine, {Carl J.} and Henry, {Timothy D.} and Schulman, {Ivonne H} and Lem Moy{\'e} and Taylor, {Doris A.} and Yang, {Phillip C.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-04801-7",
language = "English (US)",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Circulating Biomarkers to Identify Responders in Cardiac Cell therapy

AU - Jokerst, Jesse V.

AU - Cauwenberghs, Nicholas

AU - Kuznetsova, Tatiana

AU - Haddad, Francois

AU - Sweeney, Timothy

AU - Hou, Jiayi

AU - Rosenberg-Hasson, Yael

AU - Zhao, Eric

AU - Schutt, Robert

AU - Bolli, Roberto

AU - Traverse, Jay H.

AU - Pepine, Carl J.

AU - Henry, Timothy D.

AU - Schulman, Ivonne H

AU - Moyé, Lem

AU - Taylor, Doris A.

AU - Yang, Phillip C.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as well as 61 STEMI patients treated with placebo. Response to cell therapy was defined by changes in left ventricular ejection fraction, systolic/diastolic volumes, and wall motion indexes. We investigated the clinical value of circulating proteins in outcome prediction using significance testing, partial least squares discriminant analysis, and receiver operating characteristic (ROC) analysis. Responders had higher biomarker levels (76-94% elevated) than non-responders. Several biomarkers had values that differed significantly (P < 0.05) between responders and non-responders including stem cell factor, platelet-derived growth factor, and interleukin-15. We then used these lead candidates for ROC analysis and found multiple biomarkers with values areas under the curve >0.70 including interleukin 15. These biomarkers were not involved in the placebo-treated subjects suggesting that they may have predictive power. We conclude that plasma profiling after STEMI may help identify patients with a greater likelihood of response to cell-based treatment. Prospective trials are needed to assess the predictive value of the circulating biomarkers.

AB - Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as well as 61 STEMI patients treated with placebo. Response to cell therapy was defined by changes in left ventricular ejection fraction, systolic/diastolic volumes, and wall motion indexes. We investigated the clinical value of circulating proteins in outcome prediction using significance testing, partial least squares discriminant analysis, and receiver operating characteristic (ROC) analysis. Responders had higher biomarker levels (76-94% elevated) than non-responders. Several biomarkers had values that differed significantly (P < 0.05) between responders and non-responders including stem cell factor, platelet-derived growth factor, and interleukin-15. We then used these lead candidates for ROC analysis and found multiple biomarkers with values areas under the curve >0.70 including interleukin 15. These biomarkers were not involved in the placebo-treated subjects suggesting that they may have predictive power. We conclude that plasma profiling after STEMI may help identify patients with a greater likelihood of response to cell-based treatment. Prospective trials are needed to assess the predictive value of the circulating biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=85021656796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021656796&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-04801-7

DO - 10.1038/s41598-017-04801-7

M3 - Article

C2 - 28667255

AN - SCOPUS:85021656796

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 4419

ER -